

78. The method of claim 17, wherein the at least one chemical or physical attribute comprises amino acid sequence.

79. The set of ligand profiles of claim 21, wherein the at least one type of multi-ligand binding receptor is an MHC class I or MHC class II receptor.

5b  
B9 80. The set of ligand profiles of claim 21, wherein the at least one type of multi-ligand binding receptor is a chaperone, a chaperonin, a calnexin, a calreticulin, a mannosidase, a N-glycanase, a BIP, a grp94, a grp96, hsp60, hsp65, hsp70, hsp90, hsp25, an E2 ubiquitin carrier protein, an E3 ubiquitin ligase, an unfoldase, hsp100, a proteasome, a trafficking protein, or a retention protein.

81. The set of ligand profiles of claim 21, wherein the first cell is from a healthy individual and the second cell is from an individual suffering from a given disease.

82. The set of ligand profiles of claim 81, wherein the individuals are humans.

Al  
and 83. The set of ligand profiles of claim 21, wherein the first cell is from healthy tissue and the second cell is from diseased tissue.--

#### REMARKS

Claims 1-14, 17-21, and 43-83 are pending in this application. Claims 15, 16, and 22-42 have been canceled without prejudice as being drawn to non-elected inventions. Claims 43-83 are newly added by this amendment. Support for the new claims can be found in the application as follows: page 16, line 29, to page 17, line 17 (claims 43-72 and 74-80); page 25, lines 21-23 (claim 73); and page 26, lines 11-31, and page 5, lines 17-28 (claims 81-83). These amendments add no new matter.

Applicants submit that all of the claims are now in condition for examination, which action is requested. Filed herewith is a check in payment of the excess claims fees required by